Currently used serum biomarkers, such as carcinoembryonic antigen (CEA) or carbohydrate antigen 19-9 (CA19-9), are not recommended for early diagnosis, but for monitoring therapy response in advanced CRC and for detection of recurrent disease [8,9,10]. This evidence concerns the gene CEACAM5 and colorectal carcinoma.